https://orcid.org/0000-0002-3086-1210
References
- Instituto Nacional de Cancer. Estimativa 2020: incidência de câncer no Brasil [Internet]; 2020. Available from: inca.gov.br/publicacoes/livros/estimativa-2020-incidencia-de-cancer-no-brasil. Accessed April 1, 2020.
- Bironzo P, Di Maio M. A review of guidelines for lung cancer. J Thorac Dis. 2018;10(Suppl 13):S1556–63. doi:10.21037/jtd.2018.03.54
- Bridges JFP, Hauber AB, Marshall D, et al. Conjoint analysis applications in health–a checklist: a report of the ISPOR good research practices for conjoint analysis task force. Value Health. 2011;14(4):403–413. doi:10.1016/j.jval.2010.11.013
- Ryan M. Discrete choice experiments in health care. BMJ. 2004;328(7436):360–361. doi:10.1136/bmj.328.7436.360
- López-Bastida J, Ramos-Goñi JM, Aranda-Reneo I, Taruscio D, Magrelli A, Kanavos P. Using a stated preference discrete choice experiment to assess societal value from the perspective of patients with rare diseases in Italy. Orphanet J Rare Dis. 2019;14(1):154. doi:10.1186/s13023-019-1126-1
- Horne M, Jaccard M, Tiedemann K. Improving behavioral realism in hybrid energy-economy models using discrete choice studies of personal transportation decisions. Energy Economics. 2005;27(1):59–77.
- Mehdi N, Gagne Joshua J, Choudhry Niteesh K, Polinski Jennifer M, Jerry A, Schneeweiss Sebastian S. Patients’ preferences in anticoagulant therapy. Circ Cardiovasc Qual Outcomes. 2014;7(6):912–919. doi:10.1161/CIRCOUTCOMES.114.001013
- Hauber AB, González JM, Groothuis-Oudshoorn CGM, et al. Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR conjoint analysis good research practices task force. Value Health. 2016;19(4):300–315. doi:10.1016/j.jval.2016.04.004
- Ryan M, Gerard K, Amaya-Amaya M. Using discrete choice experiments to value health and health care. 2008;11.
- Mok TS, Wu Y-L, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–957. doi:10.1056/NEJMoa0810699
- Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised Phase III trial. Lancet. 2008;372(9652):1809–1818. doi:10.1016/S0140-6736(08)61758-4
- Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised Phase 3 trial. Lancet Oncol. 2012;13(3):239–246. doi:10.1016/S1470-2045(11)70393-X
- Mühlbacher AC, Bethge S. Patients’ preferences: a discrete-choice experiment for treatment of non-small-cell lung cancer. Eur J Health Econ. 2015;16(6):657–670. doi:10.1007/s10198-014-0622-4
- Bridges JF, la Cruz MD, Pavilack M, et al. Patient preferences for attributes of tyrosine kinase inhibitor treatments for EGFR mutation-positive non-small-cell lung cancer. Future Oncol. 2019;15(34):3895–3907. doi:10.2217/fon-2019-0396
- Katz SJ, Belkora J, Elwyn G. Shared decision making for treatment of cancer: challenges and opportunities. J Oncol Pract. 2014;10(3):206–208. doi:10.1200/JOP.2014.001434